These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 35227006)

  • 1. Oncolytic viruses in melanoma.
    Robinson C; Xu MM; Nair SK; Beasley GM; Rhodin KE
    Front Biosci (Landmark Ed); 2022 Feb; 27(2):63. PubMed ID: 35227006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
    Bommareddy PK; Patel A; Hossain S; Kaufman HL
    Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
    Rothermel LD; Zager JS
    Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
    Johnson DB; Puzanov I; Kelley MC
    Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
    Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
    Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
    Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
    Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
    Burke EE; Zager JS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
    Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
    Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic virus immunotherapy for melanoma.
    Dharmadhikari N; Mehnert JM; Kaufman HL
    Curr Treat Options Oncol; 2015 Mar; 16(3):326. PubMed ID: 25777572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of talimogene laherparepvec for the treatment of melanoma.
    Broman KK; Zager JS
    Expert Opin Biol Ther; 2020 Jan; 20(1):9-14. PubMed ID: 31690129
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncolytic Virotherapy: A Contest between Apples and Oranges.
    Russell SJ; Peng KW
    Mol Ther; 2017 May; 25(5):1107-1116. PubMed ID: 28392162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
    Hoffner B; Iodice GM; Gasal E
    Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
    Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
    Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ; Kaufman HL
    Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Viruses for the Treatment of Metastatic Melanoma.
    Trager MH; Geskin LJ; Saenger YM
    Curr Treat Options Oncol; 2020 Mar; 21(4):26. PubMed ID: 32266483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.